The ABC(DE) of ADTs in Advanced Prostate Cancer

Jointly provided by


Support for this activity has been provided through an educational grant from Pfizer Inc and Myovant Sciences Ltd.

Release date: 3/1/2022

Expiration date:  3/1/2023

Estimated time to complete: 1.0 hour


Prostate cancer is the most common cancer in men in the U.S., responsible for an estimated 248,530 new cases and 34,130 deaths in 2021. For patients diagnosed with advanced prostate cancer, androgen deprivation therapy (ADT) plays a major role in treatment but may be associated with a broad range of adverse effects. Of these, increased risk of cardiovascular (CV) events is among the most serious, as cardiovascular disease (CVD) is the most common non-cancer cause of death in patients with prostate cancer.

For physicians providing care to patients with advanced prostate cancer, staying current on the factors associated with safe, effective ADT use—indications for use, CVD risks, and comparative clinical efficacy of ADT agents—is essential. Of particular importance is the incorporation of the ABCDE algorithm (awareness, blood pressure monitoring, cholesterol management and cigarette avoidance, diet and diabetes, and exercise) into the advanced prostate cancer management paradigm to help prevent and manage CVD in patients with advanced prostate cancer who are receiving ADT.

Developed for urologists, oncologists, and radiation oncologists, this Virtual Practice uses a hands-on, case-based approach to discussing recommended considerations and strategies for managing CVD risk and optimizing outcomes when providing ADT to patients with advanced prostate cancer.


Alicia K. Morgans, MD, MPH—Program Chair
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Pedro Barata, MD, MSc
Assistant Professor of Medicine
Tulane University
New Orleans, Louisiana

Matthew Smith, MD, PhD
Professor of Medicine
Harvard Medical School
Director of Genitourinary Malignancies Program
Massachusetts General Hospital
Boston, Massachusetts

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, radiation oncologists, and other health care providers involved in the care and treatment of patients with advanced prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate patient CVD risk and cardiovascular safety data when selecting ADT for patients with advanced prostate cancer
  • Evaluate the clinical efficacy of gonadotropin-releasing hormone (GnRH) agonists and antagonists in the setting of advanced prostate cancer

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In accordance with the ACCME Standards for Integrity and Independence, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are discussed in the CME activity content over which the individual has control.

All relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:

Pedro Barata, MD, MSc, has disclosed the following relevant financial relationships:
Consultant (contracted research): AVEO Oncology, Merck, Seattle Genetics/Astellas
Consultant (institutional): Bayer, Dendreon, Eisai, EMD Serono, Exelixis, Janssen, Merck, Pfizer, Seattle Genetics/Astellas

Alicia Morgans, MD, MPH, has disclosed the following relevant financial relationships:
Consultant: AAA, Astellas, AstraZeneca, Bayer, Clovis, Dendreon, Janssen, Lantheus, Myriad, Myovant, Novartis, Pfizer, Sanofi, Seattle Genetics
Research Collaborator: Astellas, Bayer, Dendreon, Myovant, Sanofi, Seattle Genetics
Speaker: AAA, Astellas, AstraZeneca, Bayer, Clovis, Janssen, Merck, Myovant, Pfizer, Sanofi, Seattle Genetics

Matthew Smith, MD, PhD, has disclosed the following relevant financial relationships:
Consultant: Amgen, Astellas, Bayer, Janssen, Lilly, Pfizer

University of Cincinnati
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

The RedMedEd planners have disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the University of Cincinnati, and Pfizer Inc and Myovant Sciences Ltd do not recommend the use of any agent outside the labeled indications.


The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the University of Cincinnati, or Pfizer Inc and Myovant Sciences Ltd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit, participants must complete the program evaluation. Certificates can be printed immediately.

Contact Information

For questions regarding CME credit, contact the University of Cincinnati at
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or

Hardware/Software Requirements

  • iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge
    • Internet browsers (Mac): Chrome, Firefox, Safari 


This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by the University of Cincinnati. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the University of Cincinnati so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through the University of Cincinnati or RedMedEd. For more information, contact or

For more information about the privacy policy of the University of Cincinnati, please visit


© 2022. This CME-certified program is held as copyrighted by the University of Cincinnati and RedMedEd. Through this notice, the University of Cincinnati and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.